Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
after receiving his 2 Covid-19 vaccines his symptoms came back so he restarted; after receiving his 2 Covid-19 vaccines his symptoms came back so he restarted; This is a spontaneous report received from a Consumer or other non HCP from License Party. A 74-year-old male patient received BNT162b2 (COVID-19 VACCINE NOS MANUFACTURER UNKNOWN), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPIXENT), first regimen since 26Mar2021 (Lot number: 3F306A, Expiration Date: 30Sep2025) at 300 mg (300 mg, qow (every other week), single dose prefilled pen, strength: 300 mg/2 ml) and second regimen since 06Jan2023) at 300 mg (300 mg, qow (every other week), single dose prefilled pen), all subcutaneous for neurodermatitis. The patient's relevant medical history was not reported. Concomitant medication(s) included: DOXYCYCLINE HYCLATE; AQUAPHOR [XIPAMIDE]; SAW PALMETTO [SERENOA REPENS]; VITAMIN D3; VITAMIN E [VITAMIN E NOS]; MUPIROCIN; CLOBETASOL; CETAPHIL [ALOE VERA;PANTHENOL]; CETAPHIL [CETYL ALCOHOL;SODIUM LAURYL SULFATE;STEARYL ALCOHOL]; ROBITUSSIN COLD & COUGH; AQUAPHOR [MINERAL OIL LIGHT;PARAFFIN;PETROLATUM;WOOL ALCOHOLS]. The patient also took other concomitant therapy. Vaccination history included: Covid-19 vaccine (DOSE 1, unknown manufacturer), for COVID-19 immunization. The following information was reported: NEURODERMATITIS (non-serious), DISEASE RECURRENCE (non-serious), outcome "recovering" and all described as "after receiving his 2 Covid-19 vaccines his symptoms came back so he restarted". Therapeutic measures were taken as a result of neurodermatitis, disease recurrence. Additional information: Concomitant medications also included vitamins NOS and Cerave daily moisturizing lolion. Patient stated he started Dupixent about 3 years before an unknown date. He was symptoms free after about 1 year and stopped Dupixent, but after receiving his 2 Covid-19 vaccines his symptoms came back so he restarted. His symptoms were again well controlled and doctor agreed to have patient try to stop Dupixent to see if he could go without it. The event was reported as non-serious by Sanofi. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained. BNT162b2 is under agreement with BIONTECH SE.
DOXYCYCLINE HYCLATE; AQUAPHOR [XIPAMIDE]; SAW PALMETTO [SERENOA REPENS]; VITAMIN D3; VITAMIN E [VITAMIN E NOS]; MUPIROCIN; CLOBETASOL; CETAPHIL [ALOE VERA;PANTHENOL]; CETAPHIL [CETYL ALCOHOL;SODIUM LAURYL SULFATE;STEARYL ALCOHOL]; ROBITUSSI